Familial melanoma; CDKN2A and beyond

Journal of Investigative Dermatology Symposium Proceedings

Volumn 4, Issue 1, 1999, Pages 50-54

  Gruis, Nelleke A ^a   Van der Velden, Pieter A ^a   Bergman, Wilma ^a   Frants, Rune R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CDKN2A; Hereditary melanoma; Melanocortin 1 receptor

Indexed keywords

CYCLIN DEPENDENT KINASE; MELANOCORTIN RECEPTOR;

ALLELE; CANCER SUSCEPTIBILITY; CHROMOSOME 1P; CHROMOSOME 9P; CONFERENCE PAPER; FAMILIAL CANCER; GENE MUTATION; GENOTYPE; HUMAN; MELANOMA; PHENOTYPE;

EID: 0032870410     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jidsp.5640181     Document Type: Conference Paper

References (63)

1. Armstrong BK, Kricker A: Epidemiology of sun exposure and skin cancer. Cancer Surv 26:133-153, 1996
2. Bale SJ, Dracopoli NC, Tucker MA, et al: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 320:1367-1372, 1989
3. Bergman W, Gruis NA, Frants RR: The Dutch FAMMM family material: clinical and genetic data. Cytogenet Cell Genet 59:161-164, 1992
4. Bergman W, Gruis NA, Sandkuijl LA, Frants RR: Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J Invest Dermatol 103:122S-125S, 1994
5. Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA: Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 6:1891-1897, 1997
6. Cannon-Albright LA, Goldgar DE, Wright EC, et al: Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am J Hum Genet 46:912-918, 1990
7. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma. MLM, to chromosome 9p13- P22. Science 258:1148-1152, 1992
8. Clark WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ: Origin of familial malignant melanomas from heritable melanocytic lesions. "The BK mole syndrome". Arch Dermatol 732:732-738, 1978
9. FitzGerald MG, Harkin DP, Silva-Arrieta S, et al: Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93:8541-8545, 1996
10. Foulkes WD, Flanders TY, Pollock PM, Hayward NK: The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20, 1997
11. Gantz I, Yamada T, Tashiro T, Konda Y, Shimoto V, Miwa H, Trent JM: Mapping of the gene encoding the melanocortin-1 (alpha-melanocyte stimulating hormone) receptor (MC1R) to human chromosome 16q24.3 by Fluorescence in situ hybridization. Genomics 19:394-395, 1994
12. Goldstein AM, Goldin LR, Dracopoli NC, Clark WH Jr, Tucker MA: Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 58:1050-1056, 1996
13. Gonzalgo ML, Bender CM, You EH, et al: Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 57:5336-5347, 1997
14. Greene MH, Fraumeni JF: The hereditary variant of malignant melanoma. In: Clark WH, Goldman L, Mastrangelo M (eds). Human Malignant Melanoma. New York: Grune and Stratton, 1979, pp. 139-166
15. Greene MH, Sanders RJ, Chu FC, Clark WH Jr, Elder DE, Cogan DG: The familial occurrence of cutancous melanoma, intraocular melanoma, and the dysplastic nevus syndrome. Am J Ophthalmol 96:238-245, 1983
16. Gruis NA, Bergman W, Frants RR: Locus for susceptibility to melanoma on chromosome Ip. N Engl J Med 322:853-854, 1990
17. Gruis NA, Sandkuijl LA, Weber JL, van der Zee A, Borgstein AM, Bergman W, Frants RR: Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 3:271-277, 1993
18. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR: CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5:169-177, 1995a
19. Gruis NA, van der Velden PA, Sandkuijl LA, et al: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-353, 1995b
20. Gruis NA, Weaver-Feldhaus J, Liu Q, et al: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146:1199-1206, 1995c
21. van Haeringen A, Bergman W, Nelen MR, et al: Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 5:61-64, 1989
22. Hamada K, Kohno T, Kawanishi M, Ohwada S, Yokota J: Association of CDKN2A (p16) /CDKN2B (p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer 22:232-240, 1998
23. Harland M, Meloni R, Gruis N. et al: Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061-2067, 1997
24. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
25. Hille ET, van Duijn F, Gruis NA, Rosendaal FR, Bergman W, Vandenbroucke JP: Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to. J Invest Dermatol 110:788-792, 1998
26. Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ: Nle4DPhe7 alpha-melanocyte-stimulating honnone increases the eumelanin: phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol 104:83-85, 1995
27. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994
28. Ichii-Jones F, Lear JT, Heagerty AH, et al: Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermatol 111:218-221, 1998
29. Jadayel DM, Lukas J, Nacheva E, et al: Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 11:64-72, 1997
30. Joerg H, Fries HR, Meijerink E, Stranzinger GF: Red coat color n Holstein cattle is associated with a deletion in the MSHR gene. Mamm Genome 7:317-318, 1996
31. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994a
32. Kamb A, Shattuck-Eidens D, Eeles R, et al: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994b
33. Kamijo T, Zindy F, Roussel MF, et al: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659, 1997
34. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-8297, 1998
35. Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy WH: Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 51:45-55, 1991
36. Koppula SV, Robbins LS, Lu D, Baack H, White CR Jr, Swanson NA, Cone RD: Identification of common polymorphisms in the coding sequence of the human MSH receptor (MCIR) with possible biological effects. Hum Mutat 9:30-36, 1997
37. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D: Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412, 1995
38. Liu Q, Neuhausen S, McClure M, et al: CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067, 1995
39. Liu L, Goldstein AM, Tucker MA, Brill H, Gruis NA, Hogg D, Lassam NJ: Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer 19:52-54, 1997
40. MacGeoch C, Bishop JA, Bataille V, et al: Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 3:2195-2200, 1994
41. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD: The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248-1251, 1992
42. Nancarrow DJ, Palmer JM, Walters MK, et al: Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 12:18-25, 1992
43. Nancarrow DJ, Mann GJ, Holland EA, et al: Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53:936-942, 1993
44. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
45. Norris W: A case of fungoid disease. Edinb Med Surg J 16:562-565, 1820
46. Pollock PM, Spurr N, Bishop T, et al: Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 11:424-431, 1998
47. Quelle DE, Cheng M, Ashmun RA, Sherr CJ: Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci USA 94:669-673, 1997
48. Rizos H, Becker TM, Holland EA, Kefford RF, Mann GJ: Differential expression of p16INK4a and p16beta transcripts in B- lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene 15:515-523, 1997
49. Robbins LS, Nadeau JH, Johnson KR, et al: Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72:827-834, 1993
50. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
51. Smith R, Healy E, Siddiqui S, et al: Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 111:119-122, 1998
52. Soufir N, Avril MF, Chompret A, et al: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7:209-216, 1998
53. Stadler WM, Olopade OI: The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24:239-244, 1996
54. Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A: Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11:987-991, 1995
55. Stott FJ, Hates S, James MC, et al: The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 17:5001-5014, 1998
56. Suzuki H, Zhou X, Yin J, et al: Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum Mol Genet 4:1883-1887, 1995
57. Vage DI, Lu D, Klungland H, Lien S, Adalsteinsson S, Cone RD: A non-epistatic interaction of agouti and extension in the fox, Vulpes vulpes. Nat Genet 15:311-315, 1997
58. Valverde P, Healy F, Jackson J, Rees JL, Thody AJ: Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11:328-330, 1995
59. Valverde P, Healy E, Sikkink S, et al: The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 5:1663-1666, 1996
60. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW: Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-163, 1998
61. Weaver-Feldhaus J, Gruis NA, Neuhausen S, Le Paslier D, Stockert E, Skolnick MH, Kamb A: Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci USA 91:7563-7567, 1994
62. Xu X: Val92Met variant of the melanocyte stimulating hormone receptor gene. Nat Genet 14:384, 1996
63. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99, 1996